Cardiol Therapeutics Q4 EPS $(0.09) Beats $(0.12) Estimate
Portfolio Pulse from Benzinga Newsdesk
Cardiol Therapeutics (NASDAQ:CRDL) reported Q4 losses of $(0.09) per share, surpassing the analyst consensus estimate of $(0.12) by 25%. However, this represents a 12.5% increase in losses compared to $(0.08) per share from the same period last year.
April 02, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cardiol Therapeutics reported a smaller-than-expected loss for Q4, but its losses have widened compared to the previous year.
While beating the EPS estimate is generally positive, the increase in losses year-over-year could concern investors. The mixed results make the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100